Status:
COMPLETED
The Efficacy of Postoperative Application of HFNC at Acute Phase for Minimally Invasive Esophagectomy Surgery Patients
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Esophageal Cancer
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
This is a prospective study that uses the treatment guideline of our chest surgery ICU. Investigators recruited 90 patients who underwent MIE in the National Taiwan University Hospital. The clinical d...
Detailed Description
In recent years, for resectable esophageal cancer lesions, the National Taiwan University Hospital has developed MIE from the traditional open-abdomen and open-chest reconstructive surgeries. Because ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of esophageal cancer. Underwent minimally invasive esophagectomy surgery.
Exclusion
- 1\. The patient return to the intensive care unit without extubation 2. The patient who underwent tracheostomy surgery 3. Blood loss more than 1000c.c during the surgery 4. The patient who underwent CPR procedure or other emergent resuscitation management during surgery 5. The patient who is unable to communicate in words or speech
- \-
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2021
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT03816748
Start Date
January 1 2019
End Date
November 30 2021
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 10048